

# Antidiabetogenic Effect of Glucagon-like Peptide-1 (7â€ Patients with Diabetes Mellitus

New England Journal of Medicine

326, 1316-1322

DOI: [10.1056/nejm199205143262003](https://doi.org/10.1056/nejm199205143262003)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Enteroinsular Axis Revisited. <i>New England Journal of Medicine</i> , 1992, 326, 1352-1353.	13.9	23
2	Signal transduction crosstalk in the endocrine system: pancreatic $\beta$ -cells and the glucose competence concept. <i>Trends in Biochemical Sciences</i> , 1992, 17, 388-393.	3.7	130
3	Crosstalk among multiple signal-activated phospholipases. <i>Trends in Biochemical Sciences</i> , 1992, 17, 393-399.	3.7	240
4	Why Does the Gastric Bypass Control Type 2 Diabetes Mellitus?. <i>Obesity Surgery</i> , 1992, 2, 303-313.	1.1	67
5	Using capillary electrophoresis in the optimization of a carboxypeptidaseY catalyzed transpeptidation reaction. <i>Electrophoresis</i> , 1993, 14, 486-491.	1.3	11
6	Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1993, 36, 741-744.	2.9	1,033
7	Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). <i>Nature</i> , 1993, 361, 362-365.	13.7	561
8	Hormonal responses and future treatment of non-insulin-dependent diabetes mellitus (NIDDM)*. <i>Journal of Internal Medicine</i> , 1993, 234, 127-138.	2.7	23
9	Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man. <i>Digestive Diseases and Sciences</i> , 1993, 38, 665-673.	1.1	626
10	Effects of glucose, galactose, and lactose ingestion on the plasma glucose and insulin response in persons with non-insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1560-1567.	1.5	36
11	Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7â€“36 Amide and Glucagonlike Peptide-1 7â€“37 in Healthy Subjects Are Indistinguishable. <i>Diabetes</i> , 1993, 42, 658-661.	0.3	271
12	Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9â€“39) an Antagonist of the Receptor. <i>Diabetes</i> , 1993, 42, 1678-1682.	0.3	526
13	Effects of glucagon like-1(7â€“36)amide on the cytoplasmic Ca <sup>2+</sup> -concentration in rat islet cells. <i>Molecular and Cellular Endocrinology</i> , 1993, 96, 85-90.	1.6	40
14	In vivo expression of mutant preproendotelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3923-3927.	3.3	14
15	Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7â€“36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. <i>Journal of Molecular Endocrinology</i> , 1993, 10, 259-268.	1.1	56
16	Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.. <i>Endocrinology</i> , 1993, 133, 233-240.	1.4	225
17	Neuropeptide Y expression and regulation in a differentiated rat insulin-secreting cell line.. <i>Endocrinology</i> , 1993, 133, 1061-1067.	1.4	31
18	Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue.. <i>Endocrinology</i> , 1993, 132, 75-79.	1.4	104

#	ARTICLE	IF	CITATIONS
19	Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue.. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1654-1657.	1.8	56
20	Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.. Endocrinology, 1993, 133, 57-62.	1.4	188
21	Receptors. Digestion, 1993, 54, 341-347.	1.2	3
22	Animal Studies. Digestion, 1993, 54, 354-367.	1.2	3
23	The Incretin Notion and its Relevance to Diabetes. Endocrinology and Metabolism Clinics of North America, 1993, 22, 775-794.	1.2	68
24	1 New Hypoglycaemic Agents. Progress in Medicinal Chemistry, 1994, 31, 1-58.	4.1	22
25	Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action.. Endocrinology, 1994, 135, 589-594.	1.4	39
26	Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young. Diabetologia, 1994, 37, 721-724.	2.9	33
27	Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia, 1994, 37, 1163-1166.	2.9	145
28	Glucose-dependent alterations of intracellular free calcium by glucagon-like peptide-1(7-36amide) in individual obob mouse $\beta$ -cells. Cell Calcium, 1994, 15, 391-400.	1.1	35
29	Structure/Activity Characterization of Glucagon-Like Peptide-1. FEBS Journal, 1994, 225, 1151-1156.	0.2	83
30	The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides, 1994, 51, 63-74.	1.9	281
31	Stable expression of the rat GLP-I receptor in CHO cells: Activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides, 1994, 15, 453-456.	1.2	77
32	Regulation of Endothelin-1 Biosynthesis. Annals of the New York Academy of Sciences, 1994, 714, 109-121.	1.8	23
33	7 Humoral regulation of intestinal adaptation. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 165-183.	1.0	30
34	Glucagon-like peptide 1: A potent glycogenic hormone. FEBS Letters, 1994, 349, 313-316.	1.3	109
35	Effect of C-terminal fragments of glucagon on insulin secretion in dogs. Metabolism: Clinical and Experimental, 1994, 43, 771-775.	1.5	1
36	Interaction of glucagon-like peptide-1 (7-37) and somatostatin-14 on signal transduction and proinsulin gene expression in $\beta$ TC-1 cells. Metabolism: Clinical and Experimental, 1994, 43, 787-792.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 104-108.	1.5	176
38	Glucagon-like peptide: a therapeutic glimmer. <i>Lancet, The</i> , 1994, 343, 4-5.	6.3	22
39	Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.. <i>Endocrinology</i> , 1994, 134, 2156-2164.	1.4	282
40	Structure of Glucagon-Like Peptide(7-36) Amide in a Dodecylphosphocholine Micelle as Determined by 2D NMR. <i>Biochemistry</i> , 1994, 33, 3532-3539.	1.2	112
41	Glucagonlike peptide 1: A newly discovered gastrointestinal hormone. <i>Gastroenterology</i> , 1994, 107, 1848-1855.	0.6	245
42	Potential peptide targets in NIDDM. <i>Expert Opinion on Investigational Drugs</i> , 1994, 3, 37-39.	1.9	1
43	Inadequacy of sample sizes in clinical trials of laboratory parameters attributable to invalid statistical assumptions. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 437-444.	2.3	1
44	Detection of the Human Glucagon-Like Peptide 1(7-36) Amide Receptor on Insulinoma-Derived Cell Membranes. <i>Digestion</i> , 1994, 55, 29-33.	1.2	40
45	Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus. <i>Annals of Surgery</i> , 1995, 222, 339-352.	2.1	1,991
46	Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. <i>Endocrine Research</i> , 1995, 21, 583-594.	0.6	9
47	The Effects of Glucagon-like Peptide-I (GLP-I) on Hormone Secretion from Isolated Human Pancreatic Islets. <i>Pancreas</i> , 1995, 11, 196.	0.5	57
48	Insulinotropic action of truncated glucagon-like peptide-1 in mice. <i>Acta Physiologica Scandinavica</i> , 1995, 153, 205-206.	2.3	26
49	Failure of GLP-I(7-36)amide to affect glycogenesis in rat skeletal muscle. <i>Diabetologia</i> , 1995, 38, 864-867.	2.9	69
50	Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. <i>Acta Diabetologica</i> , 1995, 32, 13-16.	1.2	105
51	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	2.9	212
52	Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1995, 13, 841-850.	1.4	20
53	Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture. <i>Endocrine</i> , 1995, 3, 499-503.	2.2	31
54	GLP-1(7-36)amide binding in skeletal muscle membranes from streptozotocin diabetic rats. <i>Endocrine</i> , 1995, 3, 685-687.	2.2	9

#	ARTICLE	IF	CITATIONS
55	Ileal release of glucagon-like peptide-1 (GLP-1). <i>Digestive Diseases and Sciences</i> , 1995, 40, 1074-1082.	1.1	199
56	Mechanism of action of glucagon-like peptide-1(7-36)NH <sub>2</sub> in isolated rat pancreatic islets and abrogation of its effects in long-term incubations. <i>Endocrine</i> , 1995, 3, 795-799.	2.2	4
57	Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. <i>Endocrine</i> , 1995, 3, 367-369.	2.2	6
58	Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide. <i>Diabetes</i> , 1995, 44, 16-19.	0.3	177
59	Chapter 17. Recent Advancements in the Discovery and Development of Agents for the Treatment of Diabetes.. <i>Annual Reports in Medicinal Chemistry</i> , 1995, 30, 159-168.	0.5	6
60	Regulation of Islet Hormone Gene Expression by Incretin Hormones. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995, 103, 56-65.	0.6	12
61	Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells.. <i>Endocrinology</i> , 1995, 136, 4910-4917.	1.4	87
62	Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM. <i>Diabetes</i> , 1995, 44, 626-630.	0.3	144
63	Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor. <i>Diabetes</i> , 1995, 44, 1202-1208.	0.3	151
64	Activation of a cAMP-regulated Ca <sup>2+</sup> -Signaling Pathway in Pancreatic Î <sup>2</sup> -Cells by the Insulinotropic Hormone Glucagon-like Peptide-1. <i>Journal of Biological Chemistry</i> , 1995, 270, 17749-17757.	1.6	157
65	Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide. <i>Endocrine Reviews</i> , 1995, 16, 390-410.	8.9	485
66	Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. <i>Regulatory Peptides</i> , 1995, 58, 149-156.	1.9	202
67	Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice. <i>Regulatory Peptides</i> , 1995, 59, 297-302.	1.9	6
68	Glucagon-like peptide-1 binding to rat skeletal muscle. <i>Peptides</i> , 1995, 16, 225-229.	1.2	71
69	Glucose-dependent action of glucagon-like peptide-1(7-37) in vivo during short- or long-term administration. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 1231-1237.	1.5	35
70	Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. <i>FEBS Letters</i> , 1995, 358, 219-224.	1.3	362
71	Drugs on the Horizon for Treatment of Type 2 Diabetes. <i>Diabetic Medicine</i> , 1995, 12, 467-478.	1.2	29
72	Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.. <i>Endocrinology</i> , 1995, 136, 3585-3596.	1.4	977

#	ARTICLE	IF	CITATIONS
73	Glucagon and its Family Revisited. <i>Diabetes Care</i> , 1995, 18, 715-730.	4.3	107
74	chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. <i>Regulatory Peptides</i> , 1996, 63, 17-22.	1.9	40
75	Bioactive peptides from lizard venoms. <i>Regulatory Peptides</i> , 1996, 61, 1-18.	1.9	66
76	Glucagon-like peptide-1(7-36) amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1996, 1312, 132-136.	1.9	31
77	Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum. <i>Peptides</i> , 1996, 17, 571-576.	1.2	30
78	Metabolic aspects of acromegaly and its treatment. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 61-62.	1.5	10
79	Comparison of the glucose dependency of glucagon-like peptide-1(7-37) and glyburide in vitro and in vivo. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 404-409.	1.5	18
80	Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. <i>European Journal of Pharmacology</i> , 1996, 318, 429-435.	1.7	210
81	Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. <i>Regulatory Peptides</i> , 1996, 67, 63-68.	1.9	104
82	Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly. <i>Drugs</i> , 1996, 51, 931-941.	4.9	35
83	Role of prohormone convertases in the tissue-specific processing of proglucagon.. <i>Molecular Endocrinology</i> , 1996, 10, 342-355.	3.7	191
84	Effects of glucagon-like peptide-I on glucose turnover in rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1996, 270, E1015-E1021.	1.8	13
85	Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1996, 271, E458-E464.	1.8	169
86	Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1996, 271, E808-E813.	1.8	113
87	Glucagon-like Peptide-I(7-36)amide Increases Cyclic AMP Accumulation in Normal Islets. <i>Pancreas</i> , 1996, 12, 211-213.	0.5	4
88	Acute Pancreatitis After Ingestion of Acetic Acid. <i>Pancreas</i> , 1996, 12, 207-209.	0.5	7
89	An Unusual Case of Chronic Pancreatitis of Possible Immune Origin. <i>Pancreas</i> , 1996, 12, 202-204.	0.5	13
90	Pancreatitis and an Abnormal Sweat Test at Presentation in a Child with Non-Hodgkin's Lymphoma. <i>Pancreas</i> , 1996, 12, 205-206.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Induction of Diabetes in Animal Models for Pancreatic Islet Research. <i>Pancreas</i> , 1996, 12, 209-210.	0.5	0
92	Induction of Diabetes in Animal Models for Pancreatic Islet Research. <i>Pancreas</i> , 1996, 12, 211.	0.5	0
93	Absorption of glucagon-like peptide-1 can be protracted by zinc or protamine. <i>International Journal of Pharmaceutics</i> , 1996, 136, 53-59.	2.6	10
94	Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. <i>Diabetologia</i> , 1996, 39, 1546-1553.	2.9	286
95	Regulation of glucagon-like peptide-I receptor expression and transcription by the protein kinase C pathway. <i>Research in Experimental Medicine</i> , 1996, 196, 219-225.	0.7	3
96	GLP-1 does not acutely affect insulin sensitivity in healthy man. <i>Diabetologia</i> , 1996, 39, 1227-1232.	2.9	114
97	Glucagon-like peptide-1(7-36) amide and glycogen synthesis in the liver. <i>Diabetologia</i> , 1996, 39, 1241-1242.	2.9	13
98	Glucagon-like peptide-1(7-36) amide and cytoplasmic calcium in insulin producing cells. <i>Acta Physiologica Scandinavica</i> , 1996, 157, 333-341.	2.3	6
99	In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat. <i>Acta Physiologica Scandinavica</i> , 1996, 157, 359-360.	2.3	11
100	Diabetes mellitus and impaired pancreatic beta-cell proliferation. <i>Journal of Internal Medicine</i> , 1996, 239, 211-220.	2.7	33
101	Inositolphosphoglycans and diacylglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. <i>Cell Biochemistry and Function</i> , 1996, 14, 43-48.	1.4	26
102	Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice. <i>Acta Diabetologica</i> , 1996, 33, 19-24.	1.2	10
103	Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. <i>Nature Medicine</i> , 1996, 2, 1254-1258.	15.2	710
104	The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients. <i>Diabetes Care</i> , 1996, 19, 1200-1206.	4.3	67
105	Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas. <i>Diabetes Care</i> , 1996, 19, 857-863.	4.3	80
106	New treatments for patients with type 2 diabetes mellitus. <i>Postgraduate Medical Journal</i> , 1996, 72, 657-662.	0.9	28
107	Impaired Coupling of Glucose Signal to the Exocytotic Machinery in Diabetic GK Rats. <i>Diabetes</i> , 1996, 45, 934-940.	0.3	72
109	Attenuated GLP-1 secretion in obesity: cause or consequence?. <i>Gut</i> , 1996, 38, 916-919.	6.1	294

#	ARTICLE	IF	CITATIONS
110	Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 327-332.	1.8	422
111	Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet. Diabetes Care, 1996, 19, 843-848.	4.3	107
112	Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2*. Endocrinology, 1997, 138, 4837-4843.	1.4	118
113	Scanning of the Glucagon-Like Peptide-1 Receptor Localizes G Protein-Activating Determinants Primarily to the N Terminus of the Third Intracellular Loop. Molecular Endocrinology, 1997, 11, 424-432.	3.7	65
114	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 473-478.	1.8	124
115	Subcutaneous Glucagon-Like Peptide I Combined With Insulin Normalizes Postcibal Glycemic Excursions in IDDM. Diabetes Care, 1997, 20, 381-384.	4.3	37
116	Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. Journal of Molecular Endocrinology, 1997, 19, 241-248.	1.1	45
117	Rapid Oscillations in Plasma Glucagon-Like Peptide-1 (GLP-1) in Humans: Cholinergic Control of GLP-1 Secretion via Muscarinic Receptors1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 786-790.	1.8	102
118	Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard. Journal of Biological Chemistry, 1997, 272, 4108-4115.	1.6	142
119	No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. European Journal of Endocrinology, 1997, 137, 643-649.	1.9	13
120	The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7915-7920.	3.3	72
121	Design of the Entero-Insular Axis. Frontiers in Diabetes, 1997, 13, 1-14.	0.4	3
122	The Effects of GLP-1 on Insulin Release in Young and Old Rats in the Fasting State and During an Intravenous Glucose Tolerance Test. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1997, 52A, B245-B249.	1.7	15
123	Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Drugs, 1997, 54, 355-368.	4.9	123
124	Glucoregulation after canine islet transplantation: Contribution of insulin secretory capacity, insulin action, and the entero-insular axis. Cell Transplantation, 1997, 6, 497-503.	1.2	3
125	Exendin-4 Agonist and Exendin(9-39)amide Antagonist of the GLP-1(7-36)amide Effects in Liver and Muscle. Archives of Biochemistry and Biophysics, 1997, 341, 1-7.	1.4	69
126	Extrapancratic action of truncated glucagon-like peptide-I in otsuka long-evans tokushima fatty rats, an animal model for non-â€”insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1997, 46, 745-749.	1.5	30
127	Incretin hormone expression in the gut of diabetic mice and rats. Metabolism: Clinical and Experimental, 1997, 46, 261-267.	1.5	34



#	ARTICLE	IF	CITATIONS
128	Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. <i>Molecular and Cellular Endocrinology</i> , 1997, 130, 109-117.	1.6	31
129	Cloning and Characterization of the 5' Flanking Sequences (Promoter Region) of the Human GLP-1 Receptor Gene. <i>Peptides</i> , 1997, 18, 617-624.	1.2	25
130	Gastric Inhibitory Polypeptide and Splanchnic Blood Perfusion: Augmentation of the Islet Blood Flow Increase in Hyperglycemic Rats. <i>Peptides</i> , 1997, 18, 1055-1059.	1.2	15
131	Effects of Non-Glycated and Glycated Glucagon-Like Peptide-1(7-36) Amide on Glucose Metabolism in Isolated Mouse Abdominal Muscle. <i>Peptides</i> , 1997, 18, 1327-1333.	1.2	35
132	Short-term effects of glucagon-like peptide 1 (7-36 amide) on leucine kinetics in healthy volunteers. <i>Clinical Nutrition</i> , 1997, 16, 101-102.	2.3	0
133	Cell-specific Expression of the Glucose-dependent Insulinotropic Polypeptide Gene in a Mouse Neuroendocrine Tumor Cell Line. <i>Journal of Biological Chemistry</i> , 1997, 272, 17438-17443.	1.6	32
134	Treatments for obesity. <i>Expert Opinion on Emerging Drugs</i> , 1997, 2, 1-28.	1.1	2
135	Release of GLP-1 into the Circulation. <i>Frontiers in Diabetes</i> , 1997, 13, 65-84.	0.4	3
136	In vivo Regulation of Human Islet Hormone Secretion by Glucagon-Like Peptide-1. <i>Frontiers in Diabetes</i> , 1997, 13, 132-141.	0.4	0
137	Lessons from Human Studies with Glucagon-Like Peptide-1: Potential of the Gut Hormone for Clinical Use. <i>Frontiers in Diabetes</i> , 1997, 13, 219-233.	0.4	1
138	Glucoregulation after Canine Islet Transplantation: Contribution of Insulin Secretory Capacity, Insulin Action, and the Entero-Insular Axis. <i>Cell Transplantation</i> , 1997, 6, 497-503.	1.2	4
139	Effects of GLP-1 on Gastric Acid and Pancreatic Exocrine Secretion and on Gastrointestinal Motility. <i>Frontiers in Diabetes</i> , 1997, 13, 194-206.	0.4	0
140	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E981-E988.	1.8	423
141	Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 273, C920-C927.	1.6	211
142	Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release. <i>Endocrine</i> , 1997, 6, 91-95.	2.2	26
143	Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. <i>Acta Diabetologica</i> , 1997, 34, 18-21.	1.2	88
144	Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. <i>Diabetologia</i> , 1997, 40, 205-211.	2.9	274
145	Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. <i>Acta Physiologica Scandinavica</i> , 1997, 160, 413-422.	2.3	102

#	ARTICLE	IF	CITATIONS
146	Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. <i>European Journal of Clinical Investigation</i> , 1997, 27, 533-536.	1.7	98
147	Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. <i>Journal of Cellular Physiology</i> , 1997, 172, 275-283.	2.0	76
148	Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. <i>Pharmaceutical Research</i> , 1998, 15, 254-262.	1.7	43
149	GLP-1 Receptors in Golden Syrian Hamster Islets: Identification and Functional Characterization. <i>Endocrine</i> , 1998, 8, 323-330.	2.2	2
150	Aspects of Novel Sites of Regulation of the Insulin Stimulus-Secretion Coupling in Normal and Diabetic Pancreatic Islets. <i>Endocrine</i> , 1998, 9, 1-14.	2.2	14
151	On the Treatment of Diabetes Mellitus with Glucagon-like Peptide-1. <i>Annals of the New York Academy of Sciences</i> , 1998, 865, 336-343.	1.8	24
152	Plasma Glucagon-Like Peptide-1 (7-36) Amide (GLP-1) Response to Liquid Phase, Solid Phase, and Meals of Differing Lipid Composition. <i>Nutrition</i> , 1998, 14, 433-436.	1.1	43
153	Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue. , 1998, 16, 51-56.		28
154	Novel therapeutic strategies for the treatment of Type 2 diabetes. , 1998, 14, 207-225.		32
155	Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes. <i>BioEssays</i> , 1998, 20, 642-651.	1.2	113
156	Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients. , 1998, 15, 937-945.		43
157	Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. <i>Acta Diabetologica</i> , 1998, 35, 117-129.	1.2	75
158	Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. <i>Molecular Neurobiology</i> , 1998, 18, 157-173.	1.9	29
159	Significant Changes in Blood Pressure, Glucose, and Lipids with Gastric Bypass Surgery. <i>World Journal of Surgery</i> , 1998, 22, 987-992.	0.8	137
160	Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. <i>Diabetologia</i> , 1998, 41, 271-278.	2.9	273
161	Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. <i>Diabetologia</i> , 1998, 41, 474-481.	2.9	19
162	Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. <i>Diabetologia</i> , 1998, 41, 1180-1186.	2.9	118
163	Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. <i>Diabetologia</i> , 1998, 41, 1187-1193.	2.9	34

#	ARTICLE	IF	CITATIONS
164	Glucose action 'beyond ionic events' in the pancreatic $\beta$ cell. Trends in Pharmacological Sciences, 1998, 19, 496-499.	4.0	101
165	PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regulatory Peptides, 1998, 74, 167-175.	1.9	66
166	The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide. Peptides, 1998, 19, 877-882.	1.2	61
167	Contribution of a PS1-like element to the tissue- and cell-specific expression of the human GLP-1 receptor gene. FEBS Letters, 1998, 436, 163-168.	1.3	7
168	Effect of Chronic Central Administration of Glucagon-Like Peptide-1 (7-36) Amide on Food Consumption and Body Weight in Normal and Obese Rats. Obesity, 1998, 6, 147-156.	4.0	50
169	Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line1. Endocrinology, 1998, 139, 4108-4114.	1.4	144
170	Insulinotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2399-2404.	1.8	85
171	Proglucagon Processing in an Islet Cell Line: Effects of PC1 Overexpression and PC2 Depletion1. Endocrinology, 1998, 139, 1630-1637.	1.4	35
172	Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor $\beta$ Mice*. Endocrinology, 1998, 139, 3127-3132.	1.4	83
173	Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes, 1998, 47, 1038-1045.	0.3	141
174	A synthetic glucagon-like peptide-1 analog with improved plasma stability. Journal of Endocrinology, 1998, 159, 93-102.	1.2	65
175	Effects of Glucagon-Like Peptide 1 (7-36 Amide) on Glucose Kinetics during Somatostatin-Induced Suppression of Insulin Secretion in Healthy Men. Hormone Research in Paediatrics, 1998, 49, 221-225.	0.8	21
176	Glucagon-Like Peptide 1 Improves the Ability of the $\beta$ -Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance. Diabetes, 1998, 47, 1259-1265.	0.3	44
177	Effects of Metformin on Intestinal and Pancreatic Endocrine Secretion in Type 2 (Non-Insulin-Dependent) Diabetes. , 1998, 14, 161-163.		7
178	Insulin, Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Insulin-Like Growth Factor I as Putative Mediators of the Hypolipidemic Effect of Oligofructose in Rats. Journal of Nutrition, 1998, 128, 1099-1103.	1.3	114
179	Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes. Clinical Science, 1998, 95, 325-329.	1.8	44
180	Title is missing!. Clinical Science, 1998, 95, 719.	1.8	13
181	Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes. Clinical Science, 1998, 95, 325.	1.8	16

#	ARTICLE	IF	CITATIONS
182	Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. <i>Clinical Science</i> , 1998, 95, 719-724.	1.8	56
183	GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. <i>American Journal of Physiology - Cell Physiology</i> , 1998, 275, C675-C683.	2.1	118
184	Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, G984-G992.	1.6	94
185	Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 277, E996-E1004.	1.8	44
186	Oral Triacylglycerols Regulate Plasma Glucagon-Like Peptide-1(7â€³36) and Insulin Levels in Normal and Especially in Obese Rats. <i>Journal of Nutrition</i> , 1999, 129, 46-50.	1.3	25
187	Mutations to the Third Cytoplasmic Domain of the Glucagon-Like Peptide 1 (GLP-1) Receptor Can Functionally Uncouple GLP-1-Stimulated Insulin Secretion in HIT-T15 Cells. <i>Molecular Endocrinology</i> , 1999, 13, 1305-1317.	3.7	39
188	The Glucagon-Like Peptides. <i>Endocrine Reviews</i> , 1999, 20, 876-913.	8.9	881
189	Differential Expression of a Novel Seven Transmembrane Domain Protein in Epididymal Fat from Aged and Diabetic Mice. <i>Endocrinology</i> , 1999, 140, 2859-2867.	1.4	11
190	Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1409-1415.	1.9	6
191	Gene Expression of the Human Glucagon-Like Peptide-1 Receptor Is Regulated by Sp1 and Sp3<sup>1</sup>. <i>Endocrinology</i> , 1999, 140, 624-631.	1.4	27
192	Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. <i>European Journal of Endocrinology</i> , 1999, 140, 538-544.	1.9	16
193	Potentiators and Inhibitors of Insulin Secretion. <i>Advances in Molecular and Cell Biology</i> , 1999, , 175-197.	0.1	4
194	cAMP enhances insulin secretion by an action on the ATP-sensitive K <sup>+</sup> channel-independent pathway of glucose signaling in rat pancreatic islets. <i>Diabetes</i> , 1999, 48, 1006-1012.	0.3	109
195	Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. <i>Diabetes</i> , 1999, 48, 1045-1053.	0.3	97
196	Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. <i>European Journal of Clinical Investigation</i> , 1999, 29, 610-614.	1.7	23
197	Encapsulated, Genetically Engineered Cells, Secreting Glucagonâ€like Peptideâ€1 for the Treatment of Nonâ€insulinâ€dependent Diabetes Mellitus. <i>Annals of the New York Academy of Sciences</i> , 1999, 875, 277-285.	1.8	32
198	Proteolytic cleavage of glucagon-like peptide-1 by pancreatic Î² cells and by fetal calf serum analyzed by mass spectrometry. <i>Journal of Chromatography A</i> , 1999, 852, 285-295.	1.8	3
199	Insulinotropic action of monosaccharide esters: therapeutic perspectives. <i>Diabetologia</i> , 1999, 42, 286-291.	2.9	19

#	ARTICLE	IF	CITATIONS
200	Euglycaemic hyperinsulinaemia does not affect gastric emptying in Type I and Type II diabetes mellitus. <i>Diabetologia</i> , 1999, 42, 365-372.	2.9	44
201	Is glucagon-like peptide 1 an incretin hormone?. <i>Diabetologia</i> , 1999, 42, 373-379.	2.9	100
202	Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. <i>Diabetologia</i> , 1999, 42, 856-864.	2.9	383
203	Ilial Transposition and Enteroglucagon/GLP-1 in Obesity (and Diabetic?) Surgery. <i>Obesity Surgery</i> , 1999, 9, 223-228.	1.1	165
204	Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. <i>Diabetologia</i> , 1999, 42, 45-50.	2.9	204
205	Control of Glucose Homeostasis by Incretin Hormones. <i>Diabetes Technology and Therapeutics</i> , 1999, 1, 297-305.	2.4	9
206	Glucagon-like peptide-1: a potent regulator of food intake in humans. <i>Gut</i> , 1999, 44, 81-86.	6.1	497
207	In vivo dynamic distribution of <sup>131</sup> I-glucagon-like peptide-1 (7â€³36) amide in the rat studied by gamma camera. <i>Nuclear Medicine and Biology</i> , 1999, 26, 413-420.	0.3	55
208	Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. <i>Trends in Endocrinology and Metabolism</i> , 1999, 10, 229-235.	3.1	116
209	Biological activity of GLP-1-analogues with N-terminal modifications. <i>Regulatory Peptides</i> , 1999, 79, 93-102.	1.9	82
210	Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cellsâ†. <i>Peptides</i> , 1999, 20, 943-948.	1.2	33
211	Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 134-137.	1.5	15
212	Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 252-258.	1.5	100
213	Urocortin reduces food intake and gastric emptying in lean and ob/ob obese miceâ†, â†â†. <i>Gastroenterology</i> , 1999, 116, 1287-1292.	0.6	136
214	Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. <i>Diabetes</i> , 1999, 48, 2270-2276.	0.3	1,161
215	Inhibition of carbohydrate-mediated glucagon-like peptide-I (7â€³36)amide secretion by circulating non-esterified fatty acids. <i>Clinical Science</i> , 1999, 96, 335-342.	1.8	37
216	Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7â€³36)amide secretion by circulating non-esterified fatty acids. <i>Clinical Science</i> , 1999, 96, 335.	1.8	18
217	Chapter 19. Glucagon and Glucagon-Like Peptide-1. <i>Annual Reports in Medicinal Chemistry</i> , 1999, 34, 189-198.	0.5	13

#	ARTICLE	IF	CITATIONS
218	Peptidergic Regulation of Maturation of the Stimulus-Secretion Coupling in Fetal Islet ?? Cells. <i>Pancreas</i> , 2000, 20, 282-289.	0.5	7
219	Assessment of the effects of insulin secretagogues in humans. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 271-283.	2.2	3
220	Synthesis, secretion and biological actions of the glucagon-like peptides. <i>Pediatric Diabetes</i> , 2000, 1, 49-57.	1.2	14
221	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. <i>European Journal of Pharmacology</i> , 2000, 404, 239-245.	1.7	184
222	Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db / db mice. <i>Diabetologia</i> , 2000, 43, 1319-1328.	2.9	46
223	Glucagon receptors on human islet cells contribute to glucose competence of insulin release. <i>Diabetologia</i> , 2000, 43, 1012-1019.	2.9	197
224	Adenylyl cyclase isoform expression in non-diabetic and diabetic Goto-Kakizaki (GK) rat pancreas. Evidence for distinct overexpression of type-8 adenylyl cyclase in diabetic GK rat islets. <i>Histochemistry and Cell Biology</i> , 2000, 113, 81-89.	0.8	41
225	Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2000, 72, 1111-1118.	2.2	44
226	Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 279, E88-E94.	1.8	12
227	Characterization of glucagon-like peptide-1 receptor-binding determinants. <i>Journal of Molecular Endocrinology</i> , 2000, 25, 321-335.	1.1	56
228	Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish1. <i>American Zoologist</i> , 2000, 40, 246-258.	0.7	24
229	Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats. <i>Endocrinology</i> , 2000, 141, 1936-1941.	1.4	271
230	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1043-1048.	1.8	64
231	Glucagon-Like Peptide 1 (GLP-1) in Diabetes and Aging. <i>Rejuvenation Research</i> , 2000, 3, 329-333.	0.2	6
232	Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. <i>European Journal of Endocrinology</i> , 2000, 143, 717-725.	1.9	121
233	Relief from glucose-induced over-stimulation sensitizes the adenylate cyclase-cAMP system of rat pancreatic islets. <i>Journal of Endocrinology</i> , 2000, 166, 537-544.	1.2	2
234	Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. <i>Gut</i> , 2000, 46, 622-631.	6.1	110
235	Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1. <i>Journal of Endocrinology</i> , 2000, 164, 13-19.	1.2	15

#	ARTICLE	IF	CITATIONS
236	N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2000, 1474, 13-22.	1.1	44
237	GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. <i>Regulatory Peptides</i> , 2000, 86, 103-111.	1.9	67
238	A novel silencer element repressing expression of the GLP-1 receptor gene in fibroblasts and pancreatic A-cells, but not in pancreatic B- and D-cells. <i>Peptides</i> , 2000, 21, 1169-1176.	1.2	6
239	Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 709-717.	1.5	144
240	Obesity: Pathology and Therapy. <i>Handbook of Experimental Pharmacology</i> , 2000, , .	0.9	1
241	Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish. <i>American Zoologist</i> , 2000, 40, 246-258.	0.7	18
242	Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. <i>Diabetes</i> , 2000, 49, 741-748.	0.3	543
243	Nuovi farmaci per la terapia del diabete di tipo 2. <i>L Endocrinologo</i> , 2000, 1, 15-22.	0.0	0
246	Degradation and glycemic effects of His7-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. <i>Regulatory Peptides</i> , 2001, 96, 95-104.	1.9	27
247	DIETARY FIBER AND BODY-WEIGHT REGULATION. <i>Pediatric Clinics of North America</i> , 2001, 48, 969-980.	0.9	299
248	Glucagon-Like Peptide-1 and Exendin-4 Stimulate $\beta$ -Cell Neogenesis in Streptozotocin-Treated Newborn Rats Resulting in Persistently Improved Glucose Homeostasis at Adult Age. <i>Diabetes</i> , 2001, 50, 1562-1570.	0.3	360
249	Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo. <i>Biochemistry</i> , 2001, 40, 2860-2869.	1.2	97
250	Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 281, E155-E161.	1.8	428
251	Ca <sup>2+</sup> influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 281, C740-C750.	2.1	22
252	GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2001, 281, E242-E247.	1.8	30
254	Differential Effects of Glucagon-like Peptide-1 (7-36)Amide Versus Cholecystokinin on Arginine-Induced Islet Hormone Release In Vivo and In Vitro. <i>Pancreas</i> , 2001, 22, 58-64.	0.5	14
255	Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. <i>Journal of Internal Medicine</i> , 2001, 250, 81-87.	2.7	26
256	Effect of GLP-1 Treatment on GLUT2 and GLUT4 Expression in Type 1 and Type 2 Rat Diabetic Models. <i>Endocrine</i> , 2001, 15, 241-248.	2.2	79

#	ARTICLE	IF	CITATIONS
257	Potential and Prolongation of the Insulinotropic Action of Glucagon-Like Peptide 1 by Methyl Pyruvate or Dimethyl Ester of L-Glutamic Acid in a Type 2 Diabetes Animal Model. <i>Endocrine</i> , 2001, 16, 113-116.	2.2	1
258	Involvement of Calmodulin in Glucagon-Like Peptide 1(7-36) Amide-Induced Inhibition of the ATP-Sensitive K <sup>+</sup> Channel in Mouse Pancreatic I <sup>2</sup> -Cells. <i>Experimental Physiology</i> , 2001, 86, 331-339.	0.9	17
259	Pathophysiologic mechanisms of postprandial hyperglycemia. <i>American Journal of Cardiology</i> , 2001, 88, 4-8.	0.7	33
260	Glucagon-like Peptide-1 (7-37) Augments Insulin-Mediated Glucose Uptake in Elderly Patients With Diabetes. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2001, 56, M681-M685.	1.7	19
261	A Small Molecule Ligand of the Glucagon-like Peptide 1 Receptor Targets Its Amino-terminal Hormone Binding Domain. <i>Journal of Biological Chemistry</i> , 2001, 276, 37787-37793.	1.6	67
262	Protein Kinase C $\alpha$ Activation Mediates Glucagon-Like Peptide-1-Induced Pancreatic $\beta$ -Cell Proliferation. <i>Diabetes</i> , 2001, 50, 2237-2243.	0.3	240
263	Effect of Glucagon-Like Peptide-1(7-36)-Amide on Initial Splanchnic Glucose Uptake and Insulin Action in Humans With Type 1 Diabetes. <i>Diabetes</i> , 2001, 50, 565-572.	0.3	53
264	Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. <i>Diabetes</i> , 2001, 50, 776-784.	0.3	62
265	The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, S288-S303.	0.6	125
266	Effect of GLP-1 on Lipid Metabolism in Human Adipocytes. <i>Hormone and Metabolic Research</i> , 2001, 33, 73-77.	0.7	86
267	Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3853-3860.	1.8	141
268	Action of Glucagon and Glucagon-Like Peptide-1(7-36) Amide on Lipolysis in Human Subcutaneous Adipose Tissue and Skeletal Muscle <i>in Vivo</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1229-1234.	1.8	69
269	Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 869-875.	4.3	422
270	The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. <i>European Journal of Endocrinology</i> , 2002, 146, 863-869.	1.9	105
271	Two Generations of Insulinotropic Imidazoline Compounds. <i>Diabetes</i> , 2002, 51, S448-S454.	0.3	47
272	A Potent and Highly Selective VPAC2 Agonist Enhances Glucose-Induced Insulin Release and Glucose Disposal: A Potential Therapy for Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 1453-1460.	0.3	123
273	Glucagon-Like Peptide-1 Promotes Islet Cell Growth and Inhibits Apoptosis in Zucker Diabetic Rats. <i>Endocrinology</i> , 2002, 143, 4397-4408.	1.4	462
274	Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. <i>Journal of Endocrinology</i> , 2002, 173, 465-473.	1.2	109



#	ARTICLE	IF	CITATIONS
275	Effects of Obesity Surgery on Non-Insulin-Dependent Diabetes Mellitus. <i>Archives of Surgery</i> , 2002, 137, 1109.	2.3	145
276	Evidence for Early Impairment of Glucagon-Like Peptide 1-Induced Insulin Secretion in Human Type 2 (Non Insulin-Dependent) Diabetes. <i>Hormone and Metabolic Research</i> , 2002, 34, 150-154.	0.7	74
277	Glucagon-Like Peptide-1 Augments Insulin-Mediated Glucose Uptake in the Obese State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3768-3773.	1.8	108
278	A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 958-966.	1.3	260
279	The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 487-496.	1.2	85
280	Dipeptidyl Peptidase IV Inhibition Improves Impaired Glucose Tolerance in High-Fat Diet-Fed Rats: Study Using a Fischer 344 Rat Substrain Deficient in Its Enzyme Activity. <i>The Japanese Journal of Pharmacology</i> , 2002, 88, 442-450.	1.2	57
281	Dipeptidyl Peptidase IV Inhibitor NVP-DPP728 Ameliorates Early Insulin Response and Glucose Tolerance in Aged Rats but Not in Aged Fischer 344 Rats Lacking Its Enzyme Activity. <i>The Japanese Journal of Pharmacology</i> , 2002, 88, 451-458.	1.2	24
282	Novel Peptides under Development for the Treatment of Type 1 and Type 2 Diabetes Mellitus. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2002, 2, 63-82.	1.8	10
283	Oral Mucosal Drug Delivery. <i>Clinical Pharmacokinetics</i> , 2002, 41, 661-680.	1.6	266
284	Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors. <i>Receptors and Channels</i> , 2002, 8, 179-188.	1.1	55
285	Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2002, 1, 117-125.	1.8	33
286	Gastric Inhibitory Polypeptide Analogues. <i>BioDrugs</i> , 2002, 16, 175-181.	2.2	21
287	The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases $\beta$ -cell mass in diabetic mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E745-E752.	1.8	258
288	Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. <i>Biochemical and Biophysical Research Communications</i> , 2002, 294, 1-4.	1.0	54
289	Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. <i>Biochemical and Biophysical Research Communications</i> , 2002, 298, 779-784.	1.0	124
290	The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. <i>FEBS Letters</i> , 2002, 530, 244-248.	1.3	55
291	Men at increased risk of coronary heart disease are not different from age- and weight-matched healthy controls in their postprandial triglyceride, nonesterified fatty acid, or incretin responses to sucrose. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 195-200.	1.5	6
292	Glucagon and GLP-1 stimulate IGFBP-1 secretion in Hep G2 cells without effect on IGFBP-1 mRNA. <i>Growth Hormone and IGF Research</i> , 2002, 12, 60-68.	0.5	8

#	ARTICLE	IF	CITATIONS
293	The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1282-1290.	1.8	240
294	Novel Peptides under Development for the Treatment of Type 1 and Type 2 Diabetes Mellitus. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2002, 2, 63-82.	1.8	16
295	Analogues of Glucose-Dependent Insulinotropic Polypeptide With Increased Dipeptidyl Peptidase IV Resistance. , 2000, 477, 187-195.		22
296	Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G424-G431.	1.6	162
297	Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. <i>European Journal of Pharmacology</i> , 2002, 440, 269-279.	1.7	115
298	Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. <i>Biochemical Pharmacology</i> , 2002, 63, 993-996.	2.0	80
300	Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. <i>Diabetes/Metabolism Research and Reviews</i> , 2002, 18, 430-441.	1.7	149
301	The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. <i>Diabetologia</i> , 2002, 45, 195-202.	2.9	476
302	Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. <i>Diabetologia</i> , 2002, 45, 792-797.	2.9	30
303	Glucose dependence of insulinotropic actions of pituitary adenylate cyclase-activating polypeptide in insulin-secreting INS-1 cells. <i>Pflugers Archiv European Journal of Physiology</i> , 2002, 444, 556-567.	1.3	6
304	Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. <i>Diabetic Medicine</i> , 2002, 19, 790-792.	1.2	8
305	Type 2 diabetes with onset in the elderly is not a benign disease. <i>Diabetic Medicine</i> , 2002, 19, 792-794.	1.2	0
306	A case of congenital generalized lipodystrophy with lipotrophic diabetes developing anti-insulin antibodies. <i>Diabetic Medicine</i> , 2002, 19, 794-795.	1.2	7
307	The Houssay phenomenon, another clue to Sheehan's syndrome in a diabetic. <i>Diabetic Medicine</i> , 2002, 19, 795-795.	1.2	8
308	The [C282Y/wt] heterozygous HFE genotype is associated with lower blood pressure and HDL-cholesterol in Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 796-796.	1.2	0
309	Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. <i>Diabetologia</i> , 2002, 45, 1281-1291.	2.9	60
310	Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. <i>Diabetologia</i> , 2003, -1, 1410-1415.	2.9	77
311	Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. <i>Diabetologia</i> , 2003, 46, 222-230.	2.9	117

#	ARTICLE	IF	CITATIONS
312	Gut peptides and type 2 diabetes mellitus treatment. <i>Current Diabetes Reports</i> , 2003, 3, 365-372.	1.7	117
313	Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 19, 141-150.	1.9	59
314	GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 115-123.	1.7	188
315	Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. <i>BMC Endocrine Disorders</i> , 2003, 3, 3.	0.9	74
316	Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. <i>European Journal of Clinical Investigation</i> , 2003, 27, 10-16.	1.7	57
317	A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. <i>British Journal of Pharmacology</i> , 2003, 140, 339-346.	2.7	92
318	Engineering physiologically regulated insulin secretion in non- $\beta$ cells by expressing glucagon-like peptide 1 receptor. <i>Gene Therapy</i> , 2003, 10, 1712-1720.	2.3	14
319	Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate: The Ability to Activate the Glucagon-Like Peptide 1 Receptor In Vivo. <i>Diabetes</i> , 2003, 52, 751-759.	0.3	212
320	The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists. <i>FEBS Letters</i> , 2003, 553, 342-346.	1.3	37
321	[2-Sulfo-9-fluorenylmethoxycarbonyl]-exendin-4 a long-acting glucose-lowering prodrug. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 386-391.	1.0	13
322	Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala <sup>2</sup> -substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 679-687.	1.5	17
323	Cell signalling of the GLP-1 action in rat liver. <i>Molecular and Cellular Endocrinology</i> , 2003, 204, 43-50.	1.6	78
324	Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. <i>Peptides</i> , 2003, 24, 569-578.	1.2	89
325	Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. <i>Regulatory Peptides</i> , 2003, 111, 137-144.	1.9	41
326	Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line. <i>Regulatory Peptides</i> , 2003, 113, 139-147.	1.9	20
327	Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. <i>Regulatory Peptides</i> , 2003, 116, 21-25.	1.9	80
328	Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 81-86.	1.5	54
329	Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates $\beta$ -Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats. <i>Diabetes</i> , 2003, 52, 741-750.	0.3	326

#	ARTICLE	IF	CITATIONS
330	Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2003, 12, 87-100.	1.9	197
331	The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1. Journal of Biological Chemistry, 2003, 278, 10195-10200.	1.6	90
332	Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6825-6830.	3.3	323
333	Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of Molecular Endocrinology, 2003, 31, 529-540.	1.1	35
334	Characterization of GLP-1 Effects on $\hat{\text{A}}$ -Cell Function After Meal Ingestion in Humans. Diabetes Care, 2003, 26, 2860-2864.	4.3	71
335	Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care, 2003, 26, 2929-2940.	4.3	510
336	Insulin sensitisation in the treatment of Type 2 diabetes. Expert Opinion on Investigational Drugs, 2003, 12, 307-324.	1.9	24
337	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on $\hat{\text{A}}$ -Cell Sensitivity in Type 2 and Nondiabetic Subjects. Diabetes, 2003, 52, 380-386.	0.3	513
338	Glucagon-Like Peptide 1 Induces Pancreatic $\hat{\text{A}}$ -Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor. Diabetes, 2003, 52, 124-132.	0.3	360
339	Glucagon-like peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5034-5039.	3.3	133
340	Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes. Diabetes Care, 2003, 26, 837-842.	4.3	34
341	Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus. Current Medicinal Chemistry, 2003, 10, 2471-2483.	1.2	125
343	Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E701-E707.	1.8	178
344	Valine Pyrrolidide Preserves Intact Glucose-Dependent Insulinotropic Peptide and Improves Abnormal Glucose Tolerance in Minipigs With Reduced $\hat{\text{I}}^2$ -Cell Mass. Experimental Diabetes Research, 2003, 4, 93-105.	1.0	14
345	Glucagon-like peptide-1 induces a cAMP-dependent increase of [Na <sup>+</sup> ] <sub>i</sub> associated with insulin secretion in pancreatic $\hat{\text{I}}^2$ -cells. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E1001-E1009.	1.8	28
346	Dipeptidyl Peptidase IV Inhibition in Animal Models of Diabetes. Advances in Experimental Medicine and Biology, 2004, 524, 281-291.	0.8	16
349	GLP-1: Target for a New Class of Antidiabetic Agents?. Journal of the Royal Society of Medicine, 2004, 97, 270-274.	1.1	4
350	Extrapancreatic Effects of GIP and GLP-1. Hormone and Metabolic Research, 2004, 36, 830-836.	0.7	49

#	ARTICLE	IF	CITATIONS
351	New Insights Concerning the Glucose-dependent Insulin Secretagogue Action of Glucagon-like Peptide-1 in Pancreatic $\beta$ -Cells. <i>Hormone and Metabolic Research</i> , 2004, 36, 787-794.	0.7	60
352	GIP as a Potential Therapeutic Agent?. <i>Hormone and Metabolic Research</i> , 2004, 36, 859-866.	0.7	42
353	Gut peptides in the treatment of diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 177-188.	1.9	23
354	The Role of GLP-1 in the Life and Death of Pancreatic Beta Cells. <i>Hormone and Metabolic Research</i> , 2004, 36, 804-810.	0.7	80
355	GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 867-876.	0.7	202
356	Incretin Hormones and Insulin Secretion. <i>Hormone and Metabolic Research</i> , 2004, 36, 733-734.	0.7	3
357	Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. <i>Journal of Endocrinology</i> , 2004, 180, 389-398.	1.2	49
358	Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. <i>Diabetes and Vascular Disease Research</i> , 2004, 1, 40-43.	0.9	111
359	Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3469-3473.	1.8	117
360	Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. <i>Biological Chemistry</i> , 2004, 385, 169-77.	1.2	38
361	Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4. <i>Diabetes</i> , 2004, 53, 1700-1705.	0.3	146
362	New thoughts on managing obesity. <i>Gut</i> , 2004, 53, 1044-1053.	6.1	42
363	Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E75-E81.	1.8	77
364	Islet replacement vs. regeneration: Hope or hype?. <i>Pediatric Diabetes</i> , 2004, 5, 45-56.	1.2	9
365	Glucagon-Like Peptide: The Time is Near. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 249-251.	1.2	2
366	The major glucagon-like peptide-1 metabolite, GLP-1-(9â€“36)-amide, does not affect glucose or insulin levels in mice. <i>European Journal of Pharmacology</i> , 2004, 494, 283-288.	1.7	34
367	The role of GLP-1 in the regulation of islet cell mass. <i>Cell Biochemistry and Biophysics</i> , 2004, 40, 65-77.	0.9	25
368	The role of GLP-1 in the regulation of islet cell mass. <i>Cell Biochemistry and Biophysics</i> , 2004, 2004, 65-77.	0.9	1

#	ARTICLE	IF	CITATIONS
369	Glucagon-like peptide-1 prevents beta cell glucolipototoxicity. <i>Diabetologia</i> , 2004, 47, 806-815.	2.9	300
370	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E1209-E1215.	1.8	583
371	Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. <i>Diabetes Care</i> , 2004, 27, 1335-1342.	4.3	296
372	Gastro-intestinal hormones GIP and GLP-1. <i>Annales D'Endocrinologie</i> , 2004, 65, 13-21.	0.6	38
373	Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 207-212.	0.5	8
374	Glucose-dependent insulintropic polypeptide/gastric inhibitory polypeptide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 587-606.	2.2	52
375	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1091-1102.	1.9	176
376	Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1. <i>Protein Expression and Purification</i> , 2004, , .	0.6	0
377	Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2078-2084.	1.8	670
378	Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 239-252.	1.2	9
379	Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. <i>Current Opinion in Pharmacology</i> , 2004, 4, 589-596.	1.7	108
380	Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. <i>Diabetes Research and Clinical Practice</i> , 2004, 66, 63-69.	1.1	74
381	Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1. <i>Protein Expression and Purification</i> , 2004, 36, 292-299.	0.6	13
382	GLP-1: target for a new class of antidiabetic agents?. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 270-274.	1.1	7
383	Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. <i>British Journal of Nutrition</i> , 2004, 91, 439-446.	1.2	139
384	Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E882-E890.	1.8	65
385	Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential. <i>Physiology</i> , 2005, 20, 357-365.	1.6	72
386	The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. <i>Journal of Neurochemistry</i> , 2005, 92, 798-806.	2.1	241

#	ARTICLE	IF	CITATIONS
387	KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. <i>European Journal of Pharmacology</i> , 2005, 518, 63-70.	1.7	34
388	Glucagon-like peptide 1 (GLP-1) in biology and pathology. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 91-117.	1.7	250
389	Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: A prototypical example of biopharmaceutical aggregation. <i>Journal of Pharmaceutical Sciences</i> , 2005, 94, 2749-2763.	1.6	7
390	What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. <i>Diabetologia</i> , 2005, 48, 605-607.	2.9	17
391	Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. <i>Diabetologia</i> , 2005, 48, 967-975.	2.9	75
392	Alpha cell function in health and disease: influence of glucagon-like peptide-1. <i>Diabetologia</i> , 2005, 48, 1700-1713.	2.9	235
393	Impact of Gastrointestinal Function on Glycaemic Control. , 2005, , 285-321.		0
394	Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G806-G814.	1.6	44
395	Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 377-385.	0.7	113
396	Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. <i>Journal of Molecular Endocrinology</i> , 2005, 35, 27-38.	1.1	65
397	Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. <i>Journal of Endocrinology</i> , 2005, 186, 343-352.	1.2	67
398	Participation of Protein Kinases in the Stimulant Action of GLP-1 on 2-deoxy-D-glucose Uptake by Normal Rat Skeletal Muscle. <i>Hormone and Metabolic Research</i> , 2005, 37, 275-280.	0.7	14
399	The Recombinant Rat Glucagon-Like Peptide-1 Receptor, Expressed in an $\hat{\pm}$ -Cell Line, Is Coupled to Adenylyl Cyclase Activation and Intracellular Calcium Release. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2005, 113, 182-189.	0.6	12
400	Cell-Specific Expression of Glucose-Dependent-Insulinotropic Polypeptide Is Regulated by the Transcription Factor PDX-1. <i>Endocrinology</i> , 2005, 146, 383-391.	1.4	45
401	Biologic actions and therapeutic potential of the proglucagon-derived peptides. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005, 1, 22-31.	2.9	200
402	Exenatide: a novel treatment of Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 207-222.	0.2	23
403	Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2005, 31, 233-242.	1.4	149
404	The GLP-1 system as a therapeutic target. <i>Annals of Medicine</i> , 2005, 37, 314-322.	1.5	19

#	ARTICLE	IF	CITATIONS
405	The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 705-727.	1.9	14
406	Glucagon-like peptide 1 (GLP-1) and metabolic diseases. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 746-758.	1.8	31
407	Engineered $\beta$ -cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness. <i>Life Sciences</i> , 2005, 76, 1239-1248.	2.0	4
408	Subchronic 4-month oral toxicity study of dried <i>Smallanthus sonchifolius</i> (yacon) roots as a diet supplement in rats. <i>Food and Chemical Toxicology</i> , 2005, 43, 1657-1665.	1.8	53
409	Expression and purification of exendin-4, a GLP-1 receptor agonist, in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2005, 41, 259-265.	0.6	18
410	Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?. <i>Regulatory Peptides</i> , 2005, 128, 159-165.	1.9	158
411	Glycaemic effects of incretins in Type 1 diabetes mellitus. <i>Regulatory Peptides</i> , 2005, 128, 149-157.	1.9	63
412	What do we know about the secretion and degradation of incretin hormones?. <i>Regulatory Peptides</i> , 2005, 128, 117-124.	1.9	197
413	The physiological role of GLP-1 in human: incretin, ileal brake or more?. <i>Regulatory Peptides</i> , 2005, 128, 109-115.	1.9	115
414	Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. <i>Regulatory Peptides</i> , 2005, 128, 135-148.	1.9	160
415	Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. <i>Regulatory Peptides</i> , 2005, 125, 173-177.	1.9	161
416	Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. <i>Regulatory Peptides</i> , 2005, 126, 203-211.	1.9	69
417	Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 143-149.	0.5	2
418	Effect of Glucagon-Like Peptide-1(7-36) and Exendin-4 on the Vascular Reactivity in Streptozotocin/Nicotinamide-Induced Diabetic Rats. <i>Pharmacology</i> , 2005, 74, 119-126.	0.9	46
419	Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005, 4, 361-370.	1.8	63
420	Gastrointestinal Peptide Hormones Regulating Energy and Glucose Homeostasis. , 2006, , 161-181.		1
421	2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: A Potent, Selective, and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 373-380.	2.9	26
422	Plasma levels of neuropeptides in Alzheimer's disease. <i>Gynecological Endocrinology</i> , 2006, 22, 213-218.	0.7	30



#	ARTICLE	IF	CITATIONS
423	El GLP-1: acción biológica y posibles efectos terapéuticos. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2006, 53, 256-262.	0.8	0
424	The biology of incretin hormones. <i>Cell Metabolism</i> , 2006, 3, 153-165.	7.2	1,824
425	Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 845-859.	1.2	85
426	Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 860-872.	1.2	44
427	GLP-1/exendin-4 facilitates $\beta$ -cell neogenesis in rat and human pancreatic ducts. <i>Diabetes Research and Clinical Practice</i> , 2006, 73, 107-110.	1.1	102
428	Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, 189-193.	1.1	26
430	Is Exenatide A Useful Addition to Diabetes Therapy?. <i>Endocrine Practice</i> , 2006, 12, 307-314.	1.1	6
431	Exenatide: A Novel Approach for Treatment of Type 2 Diabetes. <i>Southern Medical Journal</i> , 2006, 99, 1271-1279.	0.3	17
432	The Role of Bariatric Surgery in the Management of Type 2 Diabetes. , 2006, , 215-231.		0
433	Incretins and islet function. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006, 13, 154-161.	0.6	2
434	Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations. <i>Pediatric Diabetes</i> , 2006, 7, 122-138.	1.2	21
435	Signal Transduction of PACAP and GLP-1 in Pancreatic $\beta$ Cells. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 81-92.	1.8	37
436	On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 729-736.	1.8	16
437	Colocalization of GLP-1 and GIP in Human and Porcine Intestine. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 469-472.	1.8	41
438	Insulinotropin PACAP Potentiates Insulin Action: Stimulation of Glucose Uptake in 3T3-L1 Adipocytes. <i>Annals of the New York Academy of Sciences</i> , 2000, 921, 473-477.	1.8	11
439	Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. <i>Diabetologia</i> , 2006, 49, 253-260.	2.9	207
440	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. <i>Diabetologia</i> , 2006, 49, 452-458.	2.9	244
441	Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. <i>Diabetologia</i> , 2006, 49, 1247-1253.	2.9	37

#	ARTICLE	IF	CITATIONS
442	How do different GLP-1 mimetics differ in their actions?. <i>Current Diabetes Reports</i> , 2006, 6, 365-372.	1.7	4
443	The physiology of gastric emptying. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2006, 20, 397-407.	1.7	161
444	Antihyperglycemic activity of Tarralinã,ç, an ethanolic extract of <i>Artemisia dracunculus</i> L.. <i>Phytomedicine</i> , 2006, 13, 550-557.	2.3	130
445	â€œThe next big thingâ€•in diabetes: clinical progress on DPP-IV inhibitors. <i>Drug Development Research</i> , 2006, 67, 627-642.	1.4	34
446	Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1055-1064.	0.9	51
447	The glucagon-like peptide-1 metabolite GLP-1-(9â€“36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.	1.8	90
448	Expression and Purification of Exendin-4 Dimer in <i>Escherichia coli</i> and Its Interaction with GLP-1 Receptor In Vitro. <i>Protein and Peptide Letters</i> , 2006, 13, 823-827.	0.4	6
449	Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E779-E785.	1.8	34
450	The gastroenteroinsular response to glucose ingestion during postexercise recovery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1155-E1161.	1.8	36
451	Current Concepts in Gastric Motility in Diabetes Mellitus. <i>Current Diabetes Reviews</i> , 2006, 2, 113-130.	0.6	30
453	Impaired Gene and Protein Expression of Exocytotic Soluble N-Ethylmaleimide Attachment Protein Receptor Complex Proteins in Pancreatic Islets of Type 2 Diabetic Patients. <i>Diabetes</i> , 2006, 55, 435-440.	0.3	206
454	Transcription Factor FoxO1 Mediates Glucagon-Like Peptide-1 Effects on Pancreatic Î-Cell Mass. <i>Diabetes</i> , 2006, 55, 1190-1196.	0.3	160
455	Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus. <i>Annals of Pharmacotherapy</i> , 2007, 41, 51-60.	0.9	39
456	GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2007, 1, 193-201.	0.7	0
457	SNAREing Voltage-Gated K <sup>+</sup> and ATP-Sensitive K <sup>+</sup> Channels: Tuning Î²-Cell Excitability with Syntaxin-1A and Other Exocytotic Proteins. <i>Endocrine Reviews</i> , 2007, 28, 653-663.	8.9	97
458	Dipeptidyl Peptidase-4 Inhibitors: Clinical data and clinical implications. <i>Diabetes Care</i> , 2007, 30, 1344-1350.	4.3	181
459	Strategies to treat autoimmune diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 185-194.	1.2	0
460	The Role of Î±-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications. <i>Endocrine Reviews</i> , 2007, 28, 253-283.	8.9	319

#	ARTICLE	IF	CITATIONS
461	Effects of glucagon-like peptide-1-(7â€“36)-amide on pancreatic islet and intestinal blood perfusion in Wistar rats and diabetic GK rats. <i>Clinical Science</i> , 2007, 112, 345-351.	1.8	27
462	Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. <i>Clinical Science</i> , 2007, 113, 183-193.	1.8	24
463	DPP-4 inhibitors. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 517-533.	2.2	162
465	GLP-1 amplifies insulin signaling by up-regulation of IR <sup>2</sup> , IRS-1 and Glut4 in 3T3-L1 adipocytes. <i>Endocrine</i> , 2007, 32, 90-95.	2.2	63
466	Dendritic cellâ€“expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. <i>Journal of Experimental Medicine</i> , 2007, 204, 191-201.	4.2	305
467	Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function. <i>Drugs in R and D</i> , 2007, 8, 145-153.	1.1	19
468	High-Level Expression of Fusion Protein Containing 10 Tandem Repeated GLP-1 Analogs in Yeast <i>Pichia pastoris</i> and Its Biological Activity in a Diabetic Rat Model. <i>Bioscience, Biotechnology and Biochemistry</i> , 2007, 71, 1462-1469.	0.6	19
470	Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 856-862.	1.5	11
472	The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2007, 46, 787-802.	1.6	66
473	2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes. <i>Progress in Medicinal Chemistry</i> , 2007, 45, 63-109.	4.1	19
474	Antidiabetic Activity. , 2007, , 1323-1607.		1
475	Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2715-2735.	1.4	18
476	Proteome analysis of recombinant <i>Escherichia coli</i> producing human glucagon-like peptide-1. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 849, 323-330.	1.2	5
477	Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070509203705001-???	2.2	23
478	Incretins and other peptides in the treatment of diabetes. <i>Diabetic Medicine</i> , 2007, 24, 223-232.	1.2	63
479	Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. <i>Acta Physiologica</i> , 2008, 192, 117-125.	1.8	7
480	Off-Label Use of Exenatide for the Management of Insulin-Resistant Type 1 Diabetes Mellitus in an Obese Patient with Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2007, 27, 1449-1455.	1.2	20
481	Mechanisms of action of glucagon-like peptide 1 in the pancreas. , 2007, 113, 546-593.		561

#	ARTICLE	IF	CITATIONS
482	Continuous stimulation of human glucagon-like peptide-1 (7â€“36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. <i>Diabetologia</i> , 2007, 50, 1900-1909.	2.9	71
483	Role of cysteine 341 and arginine 348 of GLP-1 receptor in G-protein coupling. <i>Molecular Biology Reports</i> , 2007, 34, 53-60.	1.0	5
484	Oral administration of a fusion protein containing eight GLP-1 analogues produced in <i>Escherichia coli</i> BL21(DE3) in streptozotocin-induced diabetic rats. <i>Biotechnology Letters</i> , 2007, 29, 1439-1446.	1.1	11
485	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. <i>Current Diabetes Reports</i> , 2007, 7, 340-347.	1.7	41
486	Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimerâ€™s disease?. <i>Neuroscience Bulletin</i> , 2007, 23, 58-65.	1.5	24
488	Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. <i>Diabetologia</i> , 2008, 51, 632-640.	2.9	82
489	Influence of Sleeve Gastrectomy on Several Experimental Models of Obesity: Metabolic and Hormonal Implications. <i>Obesity Surgery</i> , 2008, 18, 97-108.	1.1	67
490	Les incrÃ©tines. <i>Nutrition Clinique Et Metabolisme</i> , 2008, 22, 59-65.	0.2	1
491	Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 1613-1631.	1.4	27
492	Breakfast Frequency and Quality in the Etiology of Adult Obesity and Chronic Diseases. <i>Nutrition Reviews</i> , 0, 65, 268-281.	2.6	223
493	Gut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity. <i>Drugs</i> , 2008, 68, 147-163.	4.9	24
494	Design and Synthesis of Conformationally Constrained Glucagon-Like Peptide-1 Derivatives with Increased Plasma Stability and Prolonged in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2758-2765.	2.9	73
495	New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly. <i>Drugs and Aging</i> , 2008, 25, 913-925.	1.3	61
496	GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage. <i>Molecular and Cellular Endocrinology</i> , 2008, 287, 20-29.	1.6	21
497	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 639-645.	1.1	48
498	Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2008, 34, S65-S72.	1.4	137
499	GLP-1 receptor signaling: effects on pancreatic Î²-cell proliferation and survival. <i>Diabetes and Metabolism</i> , 2008, 34, S73-S77.	1.4	118
500	Incretin-based Therapies for Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2008, 32, 131-139.	0.4	16

#	ARTICLE	IF	CITATIONS
501	The Role of Incretins in Glucose Homeostasis and Diabetes Treatment. <i>Pharmacological Reviews</i> , 2008, 60, 470-512.	7.1	681
502	Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 845-853.	1.9	53
503	The Potential Beneficial Role of Glucagon-like Peptide-1 in Endothelial Dysfunction and Heart Failure Associated with Insulin Resistance. <i>Hormone and Metabolic Research</i> , 2008, 40, 593-606.	0.7	64
504	GPR119: "Double-Dipping" for Better Glycemic Control. <i>Endocrinology</i> , 2008, 149, 2035-2037.	1.4	49
505	The GLP-1 Concept in the Treatment of Type 2 Diabetes "Still Standing at the Gate of Dawn?". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 375-377.	1.8	7
506	Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2008, 2, 129-134.	0.7	0
507	The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism. <i>Current Diabetes Reviews</i> , 2008, 4, 340-356.	0.6	42
508	Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 79-90.	0.2	5
510	Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. <i>Clinical Medicine Pathology</i> , 2008, 1, CPath.S667.	0.0	11
511	Efficacy and safety of incretin-based therapies: Clinical trial data. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, S30-S40.	0.7	62
512	Age-Dependent Decline in $\beta$ -Cell Proliferation Restricts the Capacity of $\beta$ -Cell Regeneration in Mice. <i>Diabetes</i> , 2009, 58, 1312-1320.	0.3	301
513	Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver. <i>Diabetes</i> , 2009, 58, 352-359.	0.3	42
514	Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulintropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 815-821.	2.2	123
515	Functional Characterization of N-Terminally GFP-Tagged GLP-1 Receptor. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-10.	3.0	6
516	Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2009, 9, 44-52.	0.6	2
517	Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. <i>Hospital Practice (1995)</i> , 2009, 37, 7-21.	0.5	2
518	New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus. <i>Pediatric Research</i> , 2009, 65, 370-374.	1.1	13
519	The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action. <i>Endocrinology</i> , 2009, 150, 1155-1164.	1.4	99

#	ARTICLE	IF	CITATIONS
520	Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs. <i>Drug Metabolism and Disposition</i> , 2009, 37, 545-554.	1.7	28
521	Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 14-18.	4.3	58
522	Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2009, 23, 814-825.	2.0	45
523	Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 379-386.	1.5	15
525	Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure. <i>European Journal of Pharmacology</i> , 2009, 622, 71-77.	1.7	3
526	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. <i>Diabetologia</i> , 2009, 52, 199-207.	2.9	351
527	Obesity treatment: novel peripheral targets. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 830-843.	1.1	57
528	A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. <i>Nature Chemical Biology</i> , 2009, 5, 749-757.	3.9	512
529	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 369-385.	21.5	370
530	Structure-function analysis of a series of glucagon-like peptide-1 analogs. <i>Chemical Biology and Drug Design</i> , 1998, 52, 398-409.	1.2	34
531	Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus. <i>Diabetic Medicine</i> , 2009, 26, 935-938.	1.2	8
532	Role of Surgery in Management of Type 2 Diabetes Mellitus. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 281-293.	1.9	14
533	Incretin Therapies: Effects Beyond Glycemic Control. <i>European Journal of Internal Medicine</i> , 2009, 20, S319-S328.	1.0	17
534	The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes?. <i>Molecular and Cellular Endocrinology</i> , 2009, 297, 73-85.	1.6	115
535	Incretin Therapies: Effects Beyond Glycemic Control. <i>American Journal of Medicine</i> , 2009, 122, S25-S36.	0.6	30
536	DPP-4 inhibitors. <i>Insulin</i> , 2009, 4, 15-31.	0.2	6
537	The effects of ileal transposition, gastrojejunal bypass and vertical gastroplasty on the regulation of ingestion in an experimental obesity model associated with diabetes mellitus type 2. <i>Cirug�a Espa�ola (English Edition)</i> , 2009, 85, 222-228.	0.1	1
538	Absorption, Metabolism, and Excretion of [ <sup>14</sup> C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans. <i>Drug Metabolism and Disposition</i> , 2009, 37, 536-544.	1.7	129

#	ARTICLE	IF	CITATIONS
539	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. <i>Current Diabetes Reviews</i> , 2009, 5, 266-275.	0.6	49
540	Targeting $\beta$ -cell cyclic 3'-5'-adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 1477-1492.	1.2	29
541	Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E634-E643.	1.8	102
542	Constructing glucagon like peptide-1 receptor fused with derivatives of GFP for visualizing protein-protein interaction in living cells. <i>Molecular Biology Reports</i> , 2010, 37, 2749-2755.	1.0	5
543	Intestinal effects of $\alpha$ -glucosidase inhibitors: absorption of nutrients and enterohormonal changes. <i>European Journal of Clinical Investigation</i> , 1994, 24, 25-30.	1.7	29
544	The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. <i>International Journal of Clinical Practice</i> , 2010, 64, 1402-1414.	0.8	38
545	Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 34-42.	1.1	15
546	Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. <i>Neurogastroenterology and Motility</i> , 2010, 22, 1191-e315.	1.6	114
547	Interaction of GLP-1 with NPY, VIP and galanin. <i>International Journal of Biology</i> , 2010, 2, .	0.1	0
548	Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes. <i>Journal of Receptor, Ligand and Channel Research</i> , 0, , 105.	0.7	1
549	Treatment of diabetes with glucagon-like peptide-1 gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1681-1692.	1.4	11
550	Novel therapeutics and targets for the treatment of diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2010, 3, 209-229.	1.3	19
551	Odyssey between Scylla and Charybdis through storms of carbohydrate metabolism and diabetes: a career retrospective. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E849-E867.	1.8	2
552	Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance. <i>Endocrinology</i> , 2010, 151, 4678-4687.	1.4	67
553	Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency. <i>Endocrinology</i> , 2010, 151, 2474-2482.	1.4	49
555	Bowels control brain: gut hormones and obesity. <i>Nature Reviews Endocrinology</i> , 2010, 6, 444-453.	4.3	145
556	Substituted 4-Carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibroblast Activation Protein. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6572-6583.	2.9	55
557	Oral glucose leads to a differential response in glucose, insulin, and GLP-1 in lean versus obese cats. <i>Domestic Animal Endocrinology</i> , 2010, 38, 95-102.	0.8	30

#	ARTICLE	IF	CITATIONS
558	GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders. <i>Vitamins and Hormones</i> , 2010, 84, 415-448.	0.7	49
559	Sitagliptin: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1613-1622.	0.9	35
561	A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing $\beta^2$ -cell replication and neogenesis. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 72-79.	1.1	46
562	GLP-1 signaling and the regulation of pancreatic $\beta^2$ -cells mass/function. <i>Avances En DiabetologÃa</i> , 2011, 27, 3-8.	0.1	3
565	Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 99-117.	2.2	30
566	GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 990-1000.	2.2	68
567	The future of incretin-based therapy: novel avenues—novel targets. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 158-166.	2.2	53
568	Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. <i>Gene Therapy</i> , 2011, 18, 807-816.	2.3	40
569	Axon-Like Basal Processes in Enteroendocrine Cells: Characteristics and Potential Targets. <i>Clinical and Translational Science</i> , 2011, 4, 387-391.	1.5	32
570	Antibodies in metabolic diseases. <i>New Biotechnology</i> , 2011, 28, 530-537.	2.4	14
571	Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients. <i>Regulatory Peptides</i> , 2011, 168, 39-44.	1.9	17
572	GLP-1 for type 2 diabetes. <i>Experimental Cell Research</i> , 2011, 317, 1239-1245.	1.2	78
573	Third intracellular loop of glucagon like-peptide-1 receptor is coupled with endogenous mono-ADP-ribosyltransferase — Novel type of receptor regulation?. <i>European Journal of Pharmacology</i> , 2011, 666, 35-42.	1.7	3
574	Are Sulfonylureas Less Desirable Than DPP-4 Inhibitors as Add-on to Metformin in the Treatment of Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2011, 11, 83-90.	1.7	22
575	Glucagon-like peptide-1 enhances cardiac L-type $Ca^{2+}$ currents via activation of the cAMP-dependent protein kinase A pathway. <i>Cardiovascular Diabetology</i> , 2011, 10, 6.	2.7	35
577	Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice. <i>Diabetes</i> , 2011, 60, 2397-2406.	0.3	89
578	Breakfast Frequency and Quality May Affect Glycemia and Appetite in Adults and Children. <i>Journal of Nutrition</i> , 2011, 141, 163-168.	1.3	134
579	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual $\beta^2$ -Cell Function. <i>Diabetes</i> , 2011, 60, 1599-1607.	0.3	131



#	ARTICLE	IF	CITATIONS
580	Glucagon-Like Peptide 1 Inhibits the Sirtuin Deacetylase SirT1 to Stimulate Pancreatic $\beta$ -Cell Mass Expansion. <i>Diabetes</i> , 2011, 60, 3217-3222.	0.3	46
581	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual $\beta$ -Cell Function. <i>Diabetes Care</i> , 2011, 34, 1463-1468.	4.3	143
582	Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 428-435.	0.6	27
583	New gene targets for glucagon-like peptide-1 during embryonic development and in undifferentiated pluripotent cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E494-E503.	1.8	3
584	Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-12.	3.8	56
585	Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery. <i>Isrn Endocrinology</i> , 2012, 2012, 1-13.	2.0	25
586	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. <i>Current Enzyme Inhibition</i> , 2012, 7, 205-217.	0.3	5
587	Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor. <i>Journal of Physiology</i> , 2012, 590, 5245-5255.	1.3	4
588	DPP-4 inhibition and islet function. <i>Journal of Diabetes Investigation</i> , 2012, 3, 3-10.	1.1	16
589	Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-4 inhibitors versus sulphonylurea/insulin: For GLP-1/DPP-4 inhibitors. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 21-25.	1.7	20
590	Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat. <i>Regulatory Peptides</i> , 2012, 179, 71-76.	1.9	7
591	Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect. <i>Pharmacological Reports</i> , 2012, 64, 140-149.	1.5	29
592	Targeting the glucagon receptor family for diabetes and obesity therapy. , 2012, 135, 247-278.		129
593	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2012, 8, 728-742.	4.3	971
594	$\beta$ -Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic $\beta$ INS832/13 cells. <i>Molecular and Cellular Endocrinology</i> , 2012, 364, 65-70.	1.6	35
595	Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2012, 12, 560-567.	1.7	15
596	Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. <i>Gut and Liver</i> , 2012, 6, 10-20.	1.4	250
597	Incretin based therapies: Do they hold their promise?. <i>Journal of Diabetes</i> , 2012, 4, 4-7.	0.8	1

#	ARTICLE	IF	CITATIONS
598	Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 138-149.	1.9	64
599	The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. <i>Toxicon</i> , 2012, 59, 464-471.	0.8	119
600	Glucagon like-peptide-1 receptor is covalently modified by endogenous mono-ADP-ribosyltransferase. <i>Molecular Biology Reports</i> , 2012, 39, 4375-4381.	1.0	1
601	A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db/db mice. <i>Science Bulletin</i> , 2013, 58, 2447-2453.	1.7	3
602	Breakfast and exercise contingently affect postprandial metabolism and energy balance in physically active males. <i>British Journal of Nutrition</i> , 2013, 110, 721-732.	1.2	84
603	Mechanisms of Diabetic Complications. <i>Physiological Reviews</i> , 2013, 93, 137-188.	13.1	1,943
604	Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice. <i>Archives of Oral Biology</i> , 2013, 58, 755-761.	0.8	1
605	The glucagon-like peptide 1 analogue Exenid-4 attenuates alcohol mediated behaviors in rodents. <i>Psychoneuroendocrinology</i> , 2013, 38, 1259-1270.	1.3	122
606	Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives. <i>Diabetes and Metabolism</i> , 2013, 39, 195-201.	1.4	55
607	Incretin-based therapies in the treatment of type 2 diabetes " More than meets the eye?. <i>European Journal of Internal Medicine</i> , 2013, 24, 207-212.	1.0	39
608	Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 527-541.	1.8	113
609	Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. <i>Regulatory Peptides</i> , 2013, 184, 30-39.	1.9	69
610	Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2281-2296.	0.9	22
611	GLP-1 receptor agonists in the treatment of Type 2 diabetes. <i>Diabetes Management</i> , 2013, 3, 401-413.	0.5	13
612	Persistent C-peptide. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 279-284.	1.2	9
613	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy &ndash; focus on alogliptin. <i>Drug Design, Development and Therapy</i> , 2013, 7, 989.	2.0	41
614	Glucagon-Like Peptide-1 and Its Implications in Obesity. , 0, , .		4
615	Anorexigenic postprandial responses of PYY and GLP1 to slow ice cream consumption: preservation in obese adolescents, but not in obese adults. <i>European Journal of Endocrinology</i> , 2013, 168, 429-436.	1.9	24

#	ARTICLE	IF	CITATIONS
616	Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells. <i>Journal of Endocrinology</i> , 2013, 217, 241-252.	1.2	26
617	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <i>European Diabetes Nursing</i> , 2013, 10, 31-36.	0.2	8
618	Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2013, 28, 262.	1.3	40
619	The effect of duodenojejunal bypass for type 2 diabetes mellitus patients below body mass index 25 kg/m <sup>2</sup> : one year follow-up. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 85, 109.	1.1	9
620	The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice. <i>PLoS ONE</i> , 2013, 8, e69010.	1.1	109
621	An overview of non-insulin adjunctive therapies for Type 1 diabetes. <i>Diabetes Management</i> , 2014, 4, 421-435.	0.5	1
622	Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-17.	0.5	1
623	Role of Appetite-Regulating Peptides in the Pathophysiology of Addiction: Implications for Pharmacotherapy. <i>CNS Drugs</i> , 2014, 28, 875-886.	2.7	113
624	GLP-1 receptor agonists and basal insulin in type 2 diabetes. <i>Lancet</i> , The, 2014, 384, 2180-2181.	6.3	5
625	Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 1028-1039.	1.0	10
626	Predictors of response to liraglutide in Japanese type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, 451-457.	1.1	16
627	Lixisenatide resensitizes the insulin secretory response to intravenous glucose challenge in people with type 2 diabetes—A study in both people with type 2 diabetes and healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 793-800.	2.2	23
628	Regulation of Glucose Homeostasis by GLP-1. <i>Progress in Molecular Biology and Translational Science</i> , 2014, 121, 23-65.	0.9	184
629	A Brief History of the Development of Diabetes Medications. <i>Diabetes Spectrum</i> , 2014, 27, 82-86.	0.4	139
630	Effects of Glucagon-like Peptide-1 in Diabetic Rat Small Resistance Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2014, 64, 277-284.	0.8	8
631	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. <i>World Journal of Diabetes</i> , 2014, 5, 40.	1.3	46
632	Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. <i>Osteoporosis International</i> , 2014, 25, 423-439.	1.3	70
633	Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges. <i>Diabetes Care</i> , 2014, 37, 210-216.	4.3	56

#	ARTICLE	IF	CITATIONS
634	Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014, 306, R490-R498.	0.9	24
635	GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 306, E355-E362.	1.8	51
638	Incretins: Their physiology and application in the treatment of diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 354-371.	1.7	84
639	Hormones and diet, but not body weight, control hypothalamic microglial activity. <i>Glia</i> , 2014, 62, 17-25.	2.5	203
640	Liraglutide Enhances Insulin Sensitivity by Activating AMP-Activated Protein Kinase in Male Wistar Rats. <i>Endocrinology</i> , 2014, 155, 3288-3301.	1.4	39
641	Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 610-618.	1.7	39
642	Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism. <i>Current Pharmaceutical Design</i> , 2015, 21, 3606-3620.	0.9	60
643	Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 373.	1.8	33
644	Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes. <i>Journal of Menopausal Medicine</i> , 2015, 21, 93.	0.3	32
645	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. <i>BMJ Open</i> , 2015, 5, e007791-e007791.	0.8	12
646	Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 715-717.	0.3	7
647	Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. <i>Diabetes and Metabolism</i> , 2015, 41, 6S3-6S8.	1.4	5
648	Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown. <i>Diabetes Care</i> , 2015, 38, 183-185.	4.3	0
649	Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4226-4249.	1.8	18
650	Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. <i>Journal of Physiology</i> , 2015, 593, 2185-2198.	1.3	20
651	Glucagon—Early breakthroughs and recent discoveries. <i>Peptides</i> , 2015, 67, 74-81.	1.2	91
652	Protection of pancreatic $\beta$ -cells against glucotoxicity by short-term treatment with GLP-1. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 561-567.	1.0	12
653	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. <i>Diabetes Care</i> , 2015, 38, 2250-2257.	4.3	91

#	ARTICLE	IF	CITATIONS
654	Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1020-1037.	2.9	129
655	miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers. , 2016, , 643-661.		4
657	Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats. <i>Journal of Physiology and Biochemistry</i> , 2016, 73, 387-394.	1.3	8
658	Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E620-E627.	1.8	49
659	Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition. <i>Osteoporosis International</i> , 2016, 27, 1931-1951.	1.3	37
660	The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. <i>Journal of Translational Medicine</i> , 2016, 14, 229.	1.8	51
661	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1972-1980.	4.3	198
662	Species-specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. <i>British Journal of Pharmacology</i> , 2016, 173, 27-38.	2.7	86
663	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 2026-2035.	4.3	197
664	Sulfonamide-1,3,5-triazine-thiazoles: discovery of a novel class of antidiabetic agents via inhibition of DPP-4. <i>RSC Advances</i> , 2016, 6, 83438-83447.	1.7	38
665	Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. <i>Pharmacological Reviews</i> , 2016, 68, 954-1013.	7.1	252
666	Treatment of diabetes in children. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1168-1172.	0.8	8
667	Neuroprotective Effects of rhGLP-1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury. <i>Drug Development Research</i> , 2016, 77, 124-133.	1.4	12
668	Histoire des incrustines : Du chien brun au monstre de Gila. <i>Medecine Des Maladies Metaboliques</i> , 2016, 10, 285-290.	0.1	1
669	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1579-1586.	4.3	72
670	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. <i>Diabetologia</i> , 2016, 59, 907-917.	2.9	56
671	Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity. <i>Nutrition and Diabetes</i> , 2016, 6, e191-e191.	1.5	26
672	Metabolic Response of Slowly Absorbed Carbohydrates in Type 2 Diabetes Mellitus. <i>SpringerBriefs in Systems Biology</i> , 2016, , .	0.1	1

#	ARTICLE	IF	CITATIONS
673	Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy, 2016, 16, 579-590.	1.4	15
674	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes and Endocrinology, 2016, 4, 766-780.	5.5	74
675	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 399-408.	1.8	308
676	Insulin Secretion. , 2016, , 546-555.e5.		3
677	Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy. Endocrine, 2017, 55, 113-123.	1.1	12
678	Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?. Progress in Neurobiology, 2017, 153, 100-120.	2.8	64
679	Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy, 2017, 8, 727-738.	1.2	55
680	The PI3K/Akt1-FoxO1 Translocation Pathway Mediates EXF Effects on NIT-1 Cell Survival. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 669-676.	0.6	8
681	GLP-1/Exendin-4 induces $\beta$ -cell proliferation via the epidermal growth factor receptor. Scientific Reports, 2017, 7, 9100.	1.6	29
682	The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Cell Metabolism, 2017, 26, 343-352.e2.	7.2	238
683	Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. Expert Opinion on Drug Delivery, 2017, 14, 1113-1131.	2.4	4
684	In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4-Fc fusion protein. RSC Advances, 2017, 7, 54178-54187.	1.7	5
685	Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 311-321.	1.5	3
686	Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. Journal of Internal Medicine, 2017, 281, 25-40.	2.7	24
687	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study. Diabetes, Obesity and Metabolism, 2017, 19, 773-782.	2.2	28
688	Type 1 Diabetes Treatments Based on Stem Cells. Current Diabetes Reviews, 2018, 14, 14-23.	0.6	3
689	Gut-Derived Hormones' Cardiac Effects of Ghrelin and Glucagon-Like Peptide-1. , 2017, , 139-166.		1
690	The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. European Endocrinology, 2017, 13, 56.	0.8	7

#	ARTICLE	IF	CITATIONS
691	Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification. <i>Diabetic Medicine</i> , 2018, 35, 694-706.	1.2	2
692	Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1652-1658.	2.2	11
693	Exenatide once weekly for smoking cessation. <i>Medicine (United States)</i> , 2018, 97, e9567.	0.4	9
694	Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library. <i>Scientific Reports</i> , 2018, 8, 585.	1.6	7
695	Max Bergmann award lecture: Macromolecular medicinal chemistry as applied to metabolic diseases. <i>Journal of Peptide Science</i> , 2018, 24, e3056.	0.8	1
696	Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 174-180.	1.0	15
697	Treatment approach to type 2 diabetes: Past, present and future. <i>World Journal of Diabetes</i> , 2018, 9, 209-219.	1.3	56
698	Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1655-1661.	0.9	11
699	Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Pharmacological Research</i> , 2018, 137, 219-229.	3.1	54
700	Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. <i>PLoS ONE</i> , 2018, 13, e0198024.	1.1	18
701	Non-insulin pharmacological therapies for treating type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 947-960.	0.9	25
702	Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. <i>Journal of Diabetes Investigation</i> , 2019, 10, 196-201.	1.1	32
703	Metabolic Effects of Resistant Starch Type 2: A Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. <i>Nutrients</i> , 2019, 11, 1833.	1.7	37
704	GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. <i>Cardiovascular Diabetology</i> , 2019, 18, 91.	2.7	3
705	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019, 10, 376.	1.5	68
706	Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 395-420.	0.9	5
707	Prehospital exenatide in hyperglycemic stroke—A randomized trial. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 443-448.	1.0	5
709	Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 468-484.	2.5	21

#	ARTICLE	IF	CITATIONS
710	Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers. <i>General Physiology and Biophysics</i> , 2019, 38, 343-352.	0.4	1
711	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	3.0	850
712	&lt;p&gt;Dual GIP&€“GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential&lt;p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1973-1985.	1.1	46
713	Effect of portal glucose sensing on incretin hormone secretion in a canine model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E244-E249.	1.8	7
714	Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 80.	1.5	224
715	From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 260.	1.5	71
716	Gut Peptide Agonism in the Treatment of Obesity and Diabetes. , 2019, 10, 99-124.		4
717	Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. <i>Frontiers in Endocrinology</i> , 2019, 10, 780.	1.5	3
718	Ketosis-Prone Type 2 Diabetes: A Case Series. <i>Frontiers in Endocrinology</i> , 2019, 10, 684.	1.5	13
719	Subjects with high fasting insulin also have higher postprandial GLP-1 and glucagon levels than controls with lower insulin. <i>Nutrition Research</i> , 2019, 72, 111-120.	1.3	1
720	Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance. <i>Endocrine</i> , 2019, 64, 43-47.	1.1	2
721	Gut-brain axis and addictive disorders: A review with focus on alcohol and drugs of abuse. , 2019, 196, 1-14.		58
722	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 202-208.	1.8	5
723	The effect of glucagon&€“like peptide&€1 and glucagon&€“like peptide&€2 on microcirculation: A systematic review. <i>Microcirculation</i> , 2019, 26, e12367.	1.0	10
724	Interleukin-17 acts in the hypothalamus reducing food intake. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 272-285.	2.0	20
725	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154031.	1.5	12
726	Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. <i>Brain Research</i> , 2020, 1727, 146562.	1.1	23
727	Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin&€4 treatment. <i>Journal of Neuroscience Research</i> , 2020, 98, 2357-2369.	1.3	12



#	ARTICLE	IF	CITATIONS
728	Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity. <i>MAbs</i> , 2020, 12, 1794687.	2.6	7
729	Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. <i>ACS Chemical Biology</i> , 2020, 15, 1340-1348.	1.6	11
730	Plasma glucagon-like peptide 1 was associated with hospital-acquired infections and long-term mortality in burn patients. <i>Surgery</i> , 2020, 167, 1016-1022.	1.0	4
731	Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. <i>Endocrine</i> , 2020, 70, 292-298.	1.1	9
732	Intermittent versus continuous enteral nutrition attenuates increases in insulin and leptin during short-term bed rest. <i>European Journal of Applied Physiology</i> , 2020, 120, 2083-2094.	1.2	12
733	Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach. <i>Nutrients</i> , 2021, 13, 159.	1.7	69
734	Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS. <i>Molecules</i> , 2021, 26, 889.	1.7	10
735	Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists. <i>Endocrinology and Metabolism</i> , 2021, 36, 22-29.	1.3	15
736	Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications. <i>Frontiers in Endocrinology</i> , 2021, 12, 622901.	1.5	16
738	Providing diagnosis on diabetes using cloud computing environment to the people living in rural areas of India. <i>Journal of Ambient Intelligence and Humanized Computing</i> , 2022, 13, 2829-2840.	3.3	41
739	Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1128-1135.	1.1	8
740	Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. <i>British Journal of Pharmacology</i> , 2022, 179, 677-694.	2.7	12
741	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. <i>Frontiers in Endocrinology</i> , 2021, 12, 694284.	1.5	22
742	Using adjuvant pharmacotherapy in the treatment of type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2143-2148.	0.9	4
743	Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6578.	1.8	13
744	Bioequivalence study of different brands of vildagliptin in healthy human subjects. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, .	1.1	4
745	The Role of cAMP in Beta Cell Stimulus-Secretion and Intercellular Coupling. <i>Cells</i> , 2021, 10, 1658.	1.8	22
746	Exendin(9-39)NH <sub>2</sub> : Recommendations for clinical use based on a systematic literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2419-2436.	2.2	15

#	ARTICLE	IF	CITATIONS
747	Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Postgraduate Medicine</i> , 2021, 133, 1-11.	0.9	3
748	A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	7
749	Profiling the activity of edible European macroalgae towards pharmacological targets for type 2 diabetes mellitus. <i>Applied Phycology</i> , 2021, 2, 10-21.	0.6	5
750	Bariatric Surgery and Osteoporosis. <i>Calcified Tissue International</i> , 2022, 110, 576-591.	1.5	40
751	GPCR's and Endocrinology. , 2021, , .		1
752	The Role of Incretins in Insulin Secretion. , 2010, , 57-74.		1
753	Pharmacotherapy of Diabetes: New Developments. , 2007, , .		3
754	The Gluco-Incretin Hormone Glucagon-Like Peptide-1 and Its $\beta^2$ -Cell Receptor. , 1994, , 357-379.		3
755	The Human Glucagon-Like Peptide-1 (GLP-1) Receptor. <i>Advances in Experimental Medicine and Biology</i> , 1997, 426, 113-119.	0.8	2
756	Stimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1131, 943-963.	0.8	17
757	Primates in the Experimental Pharmacology of Obesity. <i>Handbook of Experimental Pharmacology</i> , 2000, , 461-489.	0.9	9
758	Structure and Function of the Glucagon-Like Peptide-1 Receptor. <i>Handbook of Experimental Pharmacology</i> , 1996, , 255-273.	0.9	3
759	Physiology and Pathophysiology of GLP-1. <i>Handbook of Experimental Pharmacology</i> , 1996, , 275-309.	0.9	4
760	Potential of GLP-1 in Diabetes Management. <i>Handbook of Experimental Pharmacology</i> , 1996, , 311-326.	0.9	2
761	Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young. <i>Diabetologia</i> , 1994, 37, 721-724.	2.9	5
762	Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.	2.9	11
763	Proglucagon processing in porcine and human pancreas.. <i>Journal of Biological Chemistry</i> , 1994, 269, 18827-18833.	1.6	147
764	Structure-activity studies of glucagon-like peptide-1.. <i>Journal of Biological Chemistry</i> , 1994, 269, 6275-6278.	1.6	236

#	ARTICLE	IF	CITATIONS
765	Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut.. Journal of Biological Chemistry, 1994, 269, 3641-3654.	1.6	255
766	Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.. Journal of Biological Chemistry, 1993, 268, 19650-19655.	1.6	717
767	Identification and characterization of adipose surface epitopes. Biochemical Journal, 2020, 477, 2509-2541.	1.7	9
768	A New Paradigm for Type 2 Diabetes Mellitus. Annals of Surgery, 1998, 227, 637-644.	2.1	238
769	Mutagenesis facilitated crystallization of GLP-1R. IUCr, 2019, 6, 996-1006.	1.0	13
770	Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.. Journal of Clinical Investigation, 1993, 91, 301-307.	3.9	1,401
771	Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.. Journal of Clinical Investigation, 1994, 93, 2263-2266.	3.9	257
772	Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle.. Journal of Clinical Investigation, 1995, 95, 1-1.	3.9	14
773	Glucagon-like peptide-1 is a physiological incretin in rat.. Journal of Clinical Investigation, 1995, 95, 417-421.	3.9	172
774	Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.. Journal of Clinical Investigation, 1996, 97, 133-138.	3.9	108
775	Gastric emptying and release of incretin hormones after glucose ingestion in humans.. Journal of Clinical Investigation, 1996, 97, 92-103.	3.9	350
776	Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance.. Journal of Clinical Investigation, 1996, 97, 2351-2361.	3.9	82
777	Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.. Journal of Clinical Investigation, 1997, 99, 2883-2889.	3.9	150
778	Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.. Journal of Clinical Investigation, 1998, 101, 1421-1430.	3.9	220
779	Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. Journal of Clinical Investigation, 2004, 113, 635-645.	3.9	201
780	Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. Journal of Clinical Investigation, 2004, 113, 635-645.	3.9	104
781	Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. Journal of Clinical Investigation, 2007, 117, 143-152.	3.9	241
782	The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation, 2007, 117, 24-32.	3.9	510

#	ARTICLE	IF	CITATIONS
783	Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.. Journal of Clinical Investigation, 1998, 102, 764-774.	3.9	114
784	Acute Incretin Response to Oral Glucose Is Associated with Stimulation of Gastric Inhibitory Polypeptide, Not Glucagon-Like Peptide in Young Subjects. Pediatric Research, 1997, 41, 364-367.	1.1	9
785	Exenatide Alters Gene Expression of NCAM, ICAM, and VCAM in the Hippocampus of Type 2 Diabetic Model Mice. Medical Science Monitor, 2016, 22, 2664-2669.	0.5	9
786	Breakfast Frequency and Quality in the Etiology of Adult Obesity and Chronic Diseases. Nutrition Reviews, 2007, 65, 268-281.	2.6	143
787	Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice. PLoS ONE, 2008, 3, e2892.	1.1	40
788	The Glucagon-Like Peptide 1 Analogue Exendin-4 Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice. PLoS ONE, 2013, 8, e77284.	1.1	94
789	Rye-Based Evening Meals Favorably Affected Glucose Regulation and Appetite Variables at the Following Breakfast; A Randomized Controlled Study in Healthy Subjects. PLoS ONE, 2016, 11, e0151985.	1.1	49
790	The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes. British Journal of Diabetes and Vascular Disease, 2014, 14, 98.	0.6	4
791	Incretin-based therapies for patients with type 1 diabetes: a meta-analysis. Endocrine Connections, 2019, 8, 277-288.	0.8	15
792	Exenatide: a novel treatment of Type 2 diabetes. Therapy: Open Access in Clinical Medicine, 2005, 2, 207-222.	0.2	4
793	New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on Incretins. Review of Diabetic Studies, 2005, 2, 61-61.	0.5	31
794	Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents. Current Pharmaceutical Design, 2004, 10, 3651-3662.	0.9	106
795	Entero-insular axis and postprandial insulin differences in African American and European American children. American Journal of Clinical Nutrition, 2008, 88, 1277-83.	2.2	24
796	Glucagon-Like Peptide-1: An Insulinotropic Hormone With Potent Growth Factor Actions at the Pancreatic Islets of Langerhans. Growth Hormone, 2001, , 109-141.	0.2	1
797	Antidiabetic activity1. , 2002, , 948-1051.		0
800	The Incretin Modulators " Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4) Tj ETQq1 1 0.784314 rgBT /Ov		1
801	Approaches to _Cell Regeneration and Neogenesis. , 2007, , 293-309.		1
802	Treatment Strategies for Type 2 Diabetes Based on Incretin Action. , 2007, , 159-169.		2

#	ARTICLE	IF	CITATIONS
803	Insulin Secretion. , 2010, , 624-635.		0
805	Clinical Mechanistic Profiling of a Novel DPP-4 Inhibitor, Vildagliptin, for the Treatment of Type 2 Diabetes Mellitus. Japanese Journal of Clinical Pharmacology and Therapeutics, 2011, 42, 279-280.	0.1	1
806	The Effect of Duodenojejunal Bypass for T2DM Patients Below BMI 25 kg/m <sup>2</sup> in Early Postoperative Period. [Chapchi] Journal Taehan Oekwa Hakhoe, 2011, 80, 103.	1.1	3
807	Effect of acute exercise on Adiponectin and Gut hormone. Journal of the Korea Academia-Industrial Cooperation Society, 2012, 13, 1194-1202.	0.0	0
808	Molecular Basis of cAMP Signaling in Pancreatic Beta Cells. , 2014, , 1-36.		0
809	Molecular Basis of cAMP Signaling in Pancreatic Beta Cells. , 2014, , 1-35.		0
810	An introduction to glucagon. , 1993, , 1-10.		0
811	Gastrointestinale Hormone. , 1997, , 253-266.		0
812	Islet Genes Regulated by GLP-1. Frontiers in Diabetes, 1997, , 152-170.	0.4	0
813	Intestinaltrakt und Pankreas. , 1999, , 613-621.		0
814	Intestinal Proglucagon-Derived Peptides. , 1999, , 493-514.		0
815	Molecular Basis of cAMP Signaling in Pancreatic $\hat{I}^2$ Cells. , 2015, , 565-603.		2
817	Extrapancreatic Effect of Glucagon like Peptide-1. Korean Journal of Medicine, 2015, 89, 404-412.	0.1	0
818	Measurement of Insulin and Other Glucose-Regulating Peptide Hormones. , 2016, , 2657-2679.		0
820	CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Meditsinskiy Sovet, 2017, , 32-37.	0.1	1
821	Clinical aspects and prospects of using DPP-4 inhibitors. Meditsinskiy Sovet, 2019, , 24-29.	0.1	1
822	QSAR study on the Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV: The (2S)-Cyanopyrrolidine analogues. British Journal of Medical and Health Research, 2020, 07, 107-126.	0.1	0
823	Potent glycogenic effect of GLP-1(7?36)amide in rat skeletal muscle. Diabetologia, 1994, 37, 1163-1166.	2.9	1

#	ARTICLE	IF	CITATIONS
827	Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. <i>Journal of Biological Chemistry</i> , 1995, 270, 17749-57.	1.6	45
829	L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12346.	1.8	3
830	Dipeptidyl Peptidase-4 (DPP4) Inhibitors. , 2022, , 583-599.		0
831	Synthesis of 5(S)-Methyl-L-Proline containing Peptidomimetic Compounds and their In-Vitro Evaluation for Dipeptidyl Peptidase-4 Inhibition. <i>Letters in Drug Design and Discovery</i> , 2022, 19, .	0.4	0
832	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. <i>Scientific Reports</i> , 2022, 12, 154.	1.6	3
833	How to thrive in unstable environments: Gene expression profile of a riparian earthworm under abiotic stress. <i>Science of the Total Environment</i> , 2022, 817, 152749.	3.9	2
834	Effects of Diet, Lifestyle, Chrononutrition and Alternative Dietary Interventions on Postprandial Glycemia and Insulin Resistance. <i>Nutrients</i> , 2022, 14, 823.	1.7	50
835	Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022, 16, 824054.	1.4	7
837	In vitro cell cultures of Brunner's glands from male mouse to study GLP-1 receptor function. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C1260-C1269.	2.1	0
839	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-17.	2.2	36
840	Effects of GLP-1 Infusion Upon Whole-body Glucose Uptake and Skeletal Muscle Perfusion During Fed-state in Older Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 971-978.	1.8	4
843	Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
844	GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	20
845	Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. <i>EClinicalMedicine</i> , 2023, 57, 101865.	3.2	4
846	The Effect of the Sodium-Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer's Disease. <i>Biomedicines</i> , 2023, 11, 1025.	1.4	3
847	Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP) – a structured summary of a study protocol for a randomized controlled study. <i>Trials</i> , 2023, 24, .	0.7	4
848	Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. <i>Diabetologia</i> , 2023, 66, 1796-1808.	2.9	20